A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy

NCT07288710 | Recruiting

• 1 other identifier: GMU-LC-202511
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

The trial was designed as a single-center, non-interventional, prospective observational study to explore the role of a multimodal digital device in analyzing subjective and objective recovery in lung cancer patients undergoing sublobar resection versus lobectomy.

Conditions

Lung Cancer (Diagnosis); Lobectomy; Sublobar Resection

Outcome Measures

Primary Outcomes (1)

• Electronic patient-reported outcomes

  The electronic patient-reported outcomes questionnaire includes pain, cough, shortness of breath, restless sleep, fatigue, drowsiness, walking difficulties, activity limitation, and distress(0 = no symptom, 10 = most severe).

  From 1 day prior to surgery through hospital discharge (assessed up to 15 days).

Secondary Outcomes (3)

• Length of Hospital Stay

  From the day of surgery until the day of discharge, assessed up to 15 days.

• Surgical Time

  During the surgical procedure (from anesthesia induction until skin closure).

• Number of Lymph Nodes Dissected

  During the surgical procedure (from anesthesia induction until skin closure).

Study Arms (2)

Sublobar Resection Group

Patients in this group underwent sublobar resection (including segmentectomy or wedge resection). The decision for patients to receive this surgical procedure was similarly based on their routine clinical assessment, disease characteristics, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients, comparing them to the lobectomy group.

Lobectomy Group

Patients in this group underwent standard lobectomy. The decision for patients to receive this surgical procedure was based on their routine clinical assessment, diagnosis, disease staging, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with histopathologically confirmed lung cancer were consecutively recruited

You may qualify if:

• adult patients (age ≥ 18 years)
• American Society of Anesthesiologists (ASA) grade of III or below
• scheduled for VATS from March to December 2023

You may not qualify if:

• age \<18 years
• inability or poor compliance to use wearable devices
• lack of smartphone
• incomplete digital device data during hospitalization
• patients with lymph node or distant metastasis

Sponsors & Collaborators

• The First Affiliated Hospital of Guangzhou Medical University: lead

Study Sites (1)

Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Disease

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jianxing He, M.D.

CONTACT

+86-20-83337792; drjianxing.he@gmail.com

Hengrui Liang, M.D.

CONTACT

+86-20-83062114; liang_hengrui@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: November 19, 2025
• First Posted: December 17, 2025
• Study Start: March 9, 2023
• Primary Completion: December 10, 2025
• Study Completion: April 20, 2026
• Last Updated: December 17, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)